MindMed Announces First Patient Dosed in Phase 3 Voyage …
2 天之前 · MindMed’s Phase 2b study, MMED008, met its primary and key secondary endpoints and demonstrated rapid, clinically meaningful, and statistically significant improvements on the …
MindMed Announces First Patient Dosed in Phase 3 Voyage
2 天之前 · MindMed’s Phase 2b study, MMED008, met its primary and key secondary endpoints and demonstrated rapid, clinically meaningful, and statistically significant improvements on the …
Mind Med: First patient dosed in Voyage study of LSD in …
2 天之前 · Mind Medicine or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D …
MindMed Announces First Patient Dosed in Phase 3 Voyage …
2 天之前 · NEW YORK, December 16, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel …
MindMed Receives FDA Breakthrough Therapy Designation and …
2024年3月7日 · NEW YORK-- (BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage …
Mind Medicine (MindMed) Inc. (MNMD) Latest Stock News
Get the latest Mind Medicine (MindMed) Inc. (MNMD) stock news and headlines to help you in your trading and investing decisions.
News & Events :: Mind Medicine (MindMed) Inc. (MNMD)
2024年12月5日 · MindMed ACNP Congress 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
MindMed Receives FDA Breakthrough Therapy Designation and …
NEW YORK, March 07, 2024 -- (BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the "Company" or "MindMed"), a clinical stage …
MindMed Collaborators Announce Positive Topline Data from …
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel …
MindMed Announces First Patient Dosed in Phase 3 Voyage …
2 天之前 · Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain …